IMMUNOGENICITY OF RECOMBINANT VACCINIA VIRUS EXPRESSING ENV GLYCOPROTEINS: HIV

这个项目是去年完成的。 我们之前报道过， 保护性免疫可以在疫苗初治以及 重组牛痘免疫猕猴 表达SIVmne包膜糖蛋白gp 160的病毒，然后 用gp 160蛋白加强免疫。 对动物进行随访， 挑战后长达5年，以确定 感染和免疫的影响。 E11 S和未克隆 SIVmne病毒对M.束状肌 然而，在这方面， 感染了未克隆的病毒后， 比E11 S好。 在感染非克隆病毒的动物中， CD 4细胞下降的发生有明显的延迟， 免疫组动物与对照组相比（95.0q15.4wk）， 免疫动物对比对照组的41.0q12.3）。 但有 免疫组与对照组之间无显著差异 由于艾滋病需要安乐死的动物数量（2/10 vs. 5/10），也不是那些发展成艾滋病的人的平均生存时间。 所以 到目前为止，所有存活的动物都有低病毒载量， 通过PCR分析，与病毒载量减少的概念一致， 与长期生存有关。 因此，在没有 消毒免疫力，减少病毒载量可能是一个理想的 接种疫苗的终点。

This project was concluded last year. We previously reported that protective immunity can be generated in vaccinia-naive as well as vaccinia-immune macaques by immunization with recombinant vaccinia virus expressing SIVmne envelope glycoprotein gp160, followed by booster immunizations with gp160 protein. Animals were followed for up to 5 years after challenge to determine the clinical outcome of infection and the effects of immunization. Both E11S and uncloned SIVmne virus showed pathogenic potential in M. fascicularis. However, infection with the uncloned virus resulted in a more rapid disease course than E11S. Among animals infected with the uncloned virus, there was a significant delay of the onset of CD4 cell decline in immunized animals compared with the controls (95.0q15.4 wk for the immunized animals vs. 41.0q12.3 for the controls). However, there was no significant difference between the immunized and the control animals in the number that required euthanasia due to AIDS (2/10 vs. 5/10), nor the mean survival time among those that developed AIDS. So far, all surviving animals have low viral load and are positive only by PCR analysis, consistent with the notion that reduced viral load correlates with long-term survival. Therefore, in the absence of sterilizing immunity, reduction of viral load may be a desirable endpoint for vaccination.